UBS Asset Management Americas Inc. boosted its position in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 29.8% in the 4th quarter, Holdings Channel reports. The firm owned 868,316 shares of the medical equipment provider’s stock after buying an additional 199,108 shares during the quarter. UBS Asset Management Americas Inc.’s holdings in Zimmer Biomet were worth $104,780,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Private Advisor Group LLC lifted its stake in Zimmer Biomet by 18.6% in the third quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock worth $791,000 after purchasing an additional 1,057 shares during the last quarter. Jana Partners LLC lifted its stake in Zimmer Biomet by 16.6% in the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after purchasing an additional 662,497 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Zimmer Biomet by 10.0% in the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock worth $1,925,000 after purchasing an additional 1,494 shares during the last quarter. WINTON GROUP Ltd bought a new stake in Zimmer Biomet in the third quarter worth about $370,000. Finally, Cipher Capital LP bought a new stake in Zimmer Biomet in the third quarter worth about $1,225,000. 88.18% of the stock is owned by institutional investors and hedge funds.
Zimmer Biomet Holdings Inc (NYSE:ZBH) opened at $118.72 on Wednesday. The stock has a market cap of $24,393.96, a P/E ratio of 13.18, a P/E/G ratio of 2.12 and a beta of 1.08. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.83 and a current ratio of 1.52. Zimmer Biomet Holdings Inc has a 1-year low of $108.03 and a 1-year high of $133.49.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.10. The company had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.03 billion. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. Zimmer Biomet’s revenue was up 3.0% compared to the same quarter last year. During the same period last year, the company posted $2.14 earnings per share. equities analysts predict that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, January 29th. Investors of record on Friday, December 29th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.81%. The ex-dividend date of this dividend was Thursday, December 28th. Zimmer Biomet’s payout ratio is 10.65%.
In related news, VP Chad F. Phipps sold 20,826 shares of Zimmer Biomet stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $115.95, for a total transaction of $2,414,774.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Bryan C. Hanson acquired 25,077 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were acquired at an average cost of $119.68 per share, for a total transaction of $3,001,215.36. The disclosure for this purchase can be found here. Company insiders own 1.07% of the company’s stock.
Several analysts have issued reports on the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Tuesday, January 30th. BMO Capital Markets reaffirmed a “buy” rating and set a $144.00 price target on shares of Zimmer Biomet in a research note on Tuesday, January 30th. Morgan Stanley lifted their price target on shares of Zimmer Biomet from $140.00 to $150.00 in a research note on Monday, January 29th. SunTrust Banks lifted their price target on shares of Zimmer Biomet to $142.00 and gave the company a “buy” rating in a research note on Monday, January 29th. Finally, Needham & Company LLC lifted their price target on shares of Zimmer Biomet from $144.00 to $155.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $141.67.
TRADEMARK VIOLATION NOTICE: “UBS Asset Management Americas Inc. Has $104.78 Million Holdings in Zimmer Biomet Holdings Inc (ZBH)” was posted by Stock Observer and is owned by of Stock Observer. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thestockobserver.com/2018/02/21/ubs-asset-management-americas-inc-has-104-78-million-holdings-in-zimmer-biomet-holdings-inc-zbh.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.